A5052096203- COVID-19 Clinical Research Studies
- Muscle and Compartmental Disorders
- Dialysis and Renal Disease Management
- Erythropoietin and Anemia Treatment
- Hemoglobinopathies and Related Disorders
University of Bologna
2022
Policlinico S.Orsola-Malpighi
2022
Azienda USL di Bologna
2022
Introduction: High-flux hemodialysis membranes may modulate the cytokine storm of SARS-CoV-2, but their impact on chronic (CHD) patients is unknown. The aim study was evaluation asymmetric cellulose triacetate (ATA) and polymethylmethacrylate (PMMA) dialyzers inflammatory markers clinical outcomes in CHD with SARS-CoV-2. Methods: A prospective, observational SARS-CoV-2 carried out. Patients were enrolled from March 2020 to May 2021. Pre- postdialysis C-reactive protein (CRP), procalcitonin...
Chronic hemodialysis patients are at high risk of severe COVID-19 disease and death related to the infection. Anti-spike monoclonal antibodies administration reduces progression hospitalization in high-risk subjects but no clear data on end-stage renal available. We report 2 cases Bamlanivimab/Etesevimab two not hospitalized chronic with SARS-CoV2 Since they large molecules (human immunoglobulin G1) molecular weight 146,000 Da, was conducted during second hour dialysis session adverse...
Abstract BACKGROUND AND AIMS High flux haemodialysis membranes may modulate the cytokine storm of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but their impact in chronic (CHD) patients is not assessed [1, 2]. The aim study was evaluation asymmetric cellulose triacetate (ATA) and polymethylmethacrylate (PMMA) dialyzers on inflammatory markers CHD with SARS-CoV-2. METHOD A prospective, observational (age ≥18 years) affected by SARS-CoV-2 carried out. Patients were enrolled...